46 related articles for article (PubMed ID: 36952534)
1. The Use of Artificial Intelligence for Complete Cytoreduction Prediction in Epithelial Ovarian Cancer: A Narrative Review.
Parpinel G; Laudani ME; Piovano E; Zola P; Lecuru F
Cancer Control; 2023; 30():10732748231159553. PubMed ID: 36847148
[TBL] [Abstract][Full Text] [Related]
2. [Diagnostic and prognostic value of tumor markers, scores (clinical and biological) algorithms, in front of an ovarian mass suspected of an epithelial ovarian cancer: Article drafted from the French Guidelines in oncology entitled "Initial management of patients with epithelial ovarian cancer" developed by FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY under the aegis of CNGOF and endorsed by INCa].
Bendifallah S; Body G; Daraï E; Ouldamer L
Gynecol Obstet Fertil Senol; 2019 Feb; 47(2):134-154. PubMed ID: 30733191
[TBL] [Abstract][Full Text] [Related]
3. A three protein signature fails to externally validate as a biomarker to predict surgical outcome in high-grade epithelial ovarian cancer.
Hawarden A; Price M; Russell B; Wilson G; Farrelly L; Embleton-Thirsk A; Parmar M; Edmondson R
PLoS One; 2023; 18(3):e0281798. PubMed ID: 36952534
[TBL] [Abstract][Full Text] [Related]
4. Preoperative serum levels of HE4 and CA125 predict primary optimal cytoreduction in advanced epithelial ovarian cancer: a preliminary model study.
Feng LY; Liao SB; Li L
J Ovarian Res; 2020 Feb; 13(1):17. PubMed ID: 32050995
[TBL] [Abstract][Full Text] [Related]
5. A novel classification of residual disease after interval debulking surgery for advanced-stage ovarian cancer to better distinguish oncologic outcome.
Manning-Geist BL; Hicks-Courant K; Gockley AA; Clark RM; Del Carmen MG; Growdon WB; Horowitz NS; Berkowitz RS; Muto MG; Worley MJ
Am J Obstet Gynecol; 2019 Oct; 221(4):326.e1-326.e7. PubMed ID: 31082382
[TBL] [Abstract][Full Text] [Related]
6. Predictive biomarker for surgical outcome in patients with advanced primary high-grade serous ovarian cancer. Are we there yet? An analysis of the prospective biobank for ovarian cancer.
Keunecke C; Kulbe H; Dreher F; Taube ET; Chekerov R; Horst D; Hummel M; Kessler T; Pietzner K; Kassuhn W; Heitz F; Muallem MZ; Lang SM; Vergote I; Dorigo O; Lammert H; du Bois A; Angelotti T; Fotopoulou C; Sehouli J; Braicu EI
Gynecol Oncol; 2022 Aug; 166(2):334-343. PubMed ID: 35738917
[TBL] [Abstract][Full Text] [Related]
7. Predictive validity of American College of Surgeons: National Surgical Quality Improvement Project risk calculator in patients with ovarian cancer undergoing interval debulking surgery.
Manning-Geist B; Cathcart AM; Sullivan MW; Pelletier A; Cham S; Muto MG; Del Carmen M; Growdon WB; Sisodia RC; Berkowitz R; Worley M
Int J Gynecol Cancer; 2021 Oct; 31(10):1356-1362. PubMed ID: 34518239
[TBL] [Abstract][Full Text] [Related]
8. Pre-operative prediction of residual disease after interval cytoreduction for epithelial ovarian cancer using HE4.
Lof P; van de Vrie R; Korse CM; van Driel WJ; van Gent MDJM; Karlsen MA; Amant F; Lok CAR
Int J Gynecol Cancer; 2019 Oct; 29(8):1304-1310. PubMed ID: 31515411
[TBL] [Abstract][Full Text] [Related]
9. Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850).
Fagotti A; Ferrandina MG; Vizzielli G; Pasciuto T; Fanfani F; Gallotta V; Margariti PA; Chiantera V; Costantini B; Gueli Alletti S; Cosentino F; Scambia G
Int J Gynecol Cancer; 2020 Nov; 30(11):1657-1664. PubMed ID: 33028623
[TBL] [Abstract][Full Text] [Related]
10. Progress in cancer survival, mortality, and incidence in seven high-income countries 1995-2014 (ICBP SURVMARK-2): a population-based study.
Arnold M; Rutherford MJ; Bardot A; Ferlay J; Andersson TM; Myklebust TÅ; Tervonen H; Thursfield V; Ransom D; Shack L; Woods RR; Turner D; Leonfellner S; Ryan S; Saint-Jacques N; De P; McClure C; Ramanakumar AV; Stuart-Panko H; Engholm G; Walsh PM; Jackson C; Vernon S; Morgan E; Gavin A; Morrison DS; Huws DW; Porter G; Butler J; Bryant H; Currow DC; Hiom S; Parkin DM; Sasieni P; Lambert PC; Møller B; Soerjomataram I; Bray F
Lancet Oncol; 2019 Nov; 20(11):1493-1505. PubMed ID: 31521509
[TBL] [Abstract][Full Text] [Related]
11. Fresh Cut Versus Stored Cut Paraffin-embedded Tissue: Effect on Immunohistochemical Staining for Common Breast Cancer Markers.
Forse CL; Pinnaduwage D; Bull SB; Mulligan AM; Andrulis IL
Appl Immunohistochem Mol Morphol; 2019 Mar; 27(3):231-237. PubMed ID: 29553968
[TBL] [Abstract][Full Text] [Related]
12. National Trends in Extended Procedures for Ovarian Cancer Debulking Surgery.
Jones NL; Chen L; Chatterjee S; Tergas AI; Burke WM; Hou JY; Ananth CV; Neugut AI; Hershman DL; Wright JD
Int J Gynecol Cancer; 2018 Jan; 28(1):19-25. PubMed ID: 28953134
[TBL] [Abstract][Full Text] [Related]
13. British Gynaecological Cancer Society (BGCS) epithelial ovarian/fallopian tube/primary peritoneal cancer guidelines: recommendations for practice.
Fotopoulou C; Hall M; Cruickshank D; Gabra H; Ganesan R; Hughes C; Kehoe S; Ledermann J; Morrison J; Naik R; Rolland P; Sundar S
Eur J Obstet Gynecol Reprod Biol; 2017 Jun; 213():123-139. PubMed ID: 28457647
[No Abstract] [Full Text] [Related]
14. Epidemiology of ovarian cancer: a review.
Reid BM; Permuth JB; Sellers TA
Cancer Biol Med; 2017 Feb; 14(1):9-32. PubMed ID: 28443200
[TBL] [Abstract][Full Text] [Related]
15. Appropriate Recommendations for Surgical Debulking in Stage IV Ovarian Cancer.
Chern JY; Curtin JP
Curr Treat Options Oncol; 2016 Jan; 17(1):1. PubMed ID: 26714493
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
